Compare LEA & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | TFX |
|---|---|---|
| Founded | 1917 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.8B |
| IPO Year | N/A | N/A |
| Metric | LEA | TFX |
|---|---|---|
| Price | $108.34 | $120.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 10 |
| Target Price | $117.36 | ★ $134.88 |
| AVG Volume (30 Days) | ★ 644.6K | 602.6K |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.86% | 1.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.17 | N/A |
| Revenue | ★ $22,985,100,000.00 | $3,189,988,000.00 |
| Revenue This Year | N/A | $9.90 |
| Revenue Next Year | $2.03 | $10.51 |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $73.85 | $102.58 |
| 52 Week High | $113.10 | $188.87 |
| Indicator | LEA | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 58.30 |
| Support Level | $106.15 | $113.62 |
| Resistance Level | $109.77 | $117.14 |
| Average True Range (ATR) | 2.87 | 3.76 |
| MACD | 0.22 | 1.74 |
| Stochastic Oscillator | 77.33 | 98.64 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.